

Community-acquired pneumonia and survival of critically ill acute exacerbation of COPD patients in respiratory intensive care units

Huriye Berk Takir¹
Antonio M Esquinas²

¹Department of Intensive Care Unit, Sureyyapasa Chest Disease and Research Hospital, Istanbul, Turkey;

²Intensive Care and Non Invasive Ventilatory Unit, Hospital Morales Meseguer, Murcia, Spain

Dear editor

Community acquired pneumonia (CAP) leads to more than 1 million hospital admissions per year according to the severity of the disease or exacerbation of underlying comorbid conditions in the USA.^{1,2} COPD is the most frequent comorbidity in patients with pneumonia, which induces acute exacerbation of COPD and respiratory failure. In a recent study, pneumonia was the second cause (19.7%) for intensive care unit (ICU) admissions among COPD patients,³ and a long-term (12 months) follow-up showed that the mortality of the COPD patients who were admitted to ICU due to pneumonia was higher than patients admitted for other reasons.³

We read with great pleasure the recent paper by Lu et al⁴ entitled “Community-acquired pneumonia and survival of critically ill acute exacerbation of COPD patients in respiratory intensive care units” published in *International Journal of COPD*. This study was a retrospective observational design and was conducted in a respiratory intensive care unit for a 3-year period in China. They aimed to investigate the effect of CAP on hospital mortality in critically ill patients with acute exacerbation of COPD. A total of 80 patients were evaluated, of whom 38 had CAP, and they concluded that COPD patients with CAP had higher inhospital mortality than patients without CAP. This study is valuable to emphasize the mortality rates in patients with COPD and SCAP. However, we believe that there are some issues worthy for further comment.

First, there are no data about the criterion(s) for ICU admission of severe CAP (SCAP). The minor criteria of Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) 2007 were tested in clinical practice to identify SCAP cases for early aggressive resuscitation and prevent ICU admission delay.⁵ Different combinations out of 9 minor criteria of 2007 IDSA/ATS are associated with diverse mortality.⁶ Li et al⁶ investigated 385 SCAP patients in a prospective 2-center study and concluded that patients with PaO₂/FiO₂ level ≤ 250 mmHg and with confusion and uremia were predicted with more severity and higher mortality when compared with others. Chalmers et al⁷ found that each minor criterion was predictive of mortality, but hypotension, multilobar radiographic shadowing and hypothermia had the strongest association with mortality.

Second, one of the most important issues about CAP is the fact that there is very close correlation between hospital mortality, time to initiate appropriate empirical antibiotic treatment and time to respiratory intensive care unit admission. Mortality increases according to ICU admission delays.⁵ In the present study it is not clarified

Correspondence: Huriye Berk Takir
Department of Intensive Care Unit,
Sureyyapasa Chest Disease and Research
Hospital, Zmrutevler Mah., Handegul
Sok., Adatepe Sitesi A-I Blok K:4 D:11
Maltepe, Istanbul 34852, Turkey
Tel +90 505 774 5988
Email huriyebek@yahoo.com

whether the patients were admitted from the emergency department or general ward. COPD patients were predisposed to pneumonia with several microorganisms such as *Pseudomonas aeruginosa* and *Legionella pneumophila*. Because COPD patients use corticosteroids and antibiotics, have malnutrition and frequent hospital admissions. It is undetermined in the study whether empiric antibiotic treatment covers these probable microorganisms.

We believe that a resuscitation bundle should be performed, including appropriate empiric antibiotic treatment, fluid challenge, organ failure and tissue hypoperfusion assessments, immediately after the COPD patients are encountered with SCAP in order to reduce mortality.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. *Vital Health Stat* 13. 2005;158:1–199.
2. Kung HC, Hoyert DL, Xu JQ, Murphy SL. *Deaths Final Data for 2005: National Vital Statistics Reports*. Vol. 56. Hyattsville, MD: National Center for Health Statistics; 2008.
3. Takir HB, Karakurt Z, Salturk C, et al. Reasons for ICU demand and long-term follow-up of a chronic obstructive pulmonary disease cohort. *COPD*. 2014;11(6):627–638.
4. Lu Z, Cheng Y, Tu X, et al. Community-acquired pneumonia and survival of critically ill acute exacerbation of COPD patients in respiratory intensive care units. *Int J Chron Obstruct Pulmon Dis*. 2016;11:1867–1872.
5. Lim HF, Phua J, Mukhopadhyay A, et al. IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia. *Eur Respir J*. 2014;43(3):852–862.
6. Li HY, Guo Q, Song WD, et al. Mortality among severe community-acquired pneumonia patients depends on combinations of 2007 IDSA/ATS minor criteria. *Int J Infect Dis*. 2015;38:141–145.
7. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoracic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. *Clin Infect Dis*. 2011;53(6):503–511.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the International Journal of Chronic Obstructive Pulmonary Disease 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the International Journal of Chronic Obstructive Pulmonary Disease editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

International Journal of COPD

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress